BCM
NVCR icon

Brookstone Capital Management’s NovoCure NVCR Stock Holding History

Brookstone Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,416
Closed -$937K – 533
2020
Q4 		$937K Buy
+5,416
New +$741K 0.04% 240

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brookstone Capital Management's NVCR Position: Q1 2021 in Review

Brookstone Capital Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 5,416 shares — an estimated $937K sold.

Brookstone Capital Management first reported a position in NVCR in Q4 2020 and held it in 1 quarter. The position peaked at $937K in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Brookstone Capital Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Brookstone Capital Management sold 5,416 NovoCure shares in Q1 2021, an estimated $937K.
  • Brookstone Capital Management first reported a position in NovoCure in Q4 2020 and held it in 1 quarter.
  • Brookstone Capital Management's NovoCure position peaked at $937K in Q4 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Brookstone Capital Management's 13F filing for Q1 2021, filed 16 Apr 2021.